Eugia Sez Profile
Key Indicators
- Authorised Capital ₹ 360.00 Cr
as on 30-10-2024
- Paid Up Capital ₹ 4.00 Cr
as on 30-10-2024
- Company Age 3 Year, 9 Months
- Last Filing with ROC 31 Mar 2024
- Revenue 7.73%
(FY 2023)
- Profit -1627.96%
(FY 2023)
- Ebitda -208.15%
(FY 2023)
- Net Worth -613.00%
(FY 2023)
- Total Assets 3.10%
(FY 2023)
About Eugia Sez
The Corporate was formerly known as Wytells Pharma Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 360.00 Cr and a paid-up capital of Rs 4.00 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Eugia Sez Private Limited India are Venkat Kupireddy as COMPANY SECRETARY and Vallamkondu Kumar as Cfo. Madan Mettu, Santhanam Subramanian, Vijay Natarajan, and One other member serve as directors at the Company.
- CIN/LLPIN
U24299TG2021PTC148856
- Company No.
148856
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
20 Feb 2021
- Date of AGM
22 Jul 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Rangareddy, Telangana, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Eugia Sez?
Executive Team (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Venkat Kupireddy  | Company Secretary | 08-Jul-2022 | Current |
| Vallamkondu Kumar | CFO | 21-Feb-2024 | Current |
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Vijay Natarajan | Director | 20-Feb-2021 | Current |
| Madan Mettu | Director | 20-Feb-2021 | Current |
| Santhanam Subramanian | Director | 20-Feb-2021 | Current |
| Mylandlahalli Ashwini | Director | 12-Jun-2024 | Current |
Financial Performance and Corporate Structure Insights of Eugia Sez.
Eugia Sez Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 7.73% increase. The company also saw a substantial fall in profitability, with a 1627.96% decrease in profit. The company's net worth observed a substantial decline by a decrease of 613%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Eugia Sez?
In 2023, Eugia Sez had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Eugia Pharma Specialities LimitedActive 11 years 8 monthsMadan Mettu, Santhanam Subramanian and 2 more are mutual person
- Curateq Biologics Private LimitedActive 4 years 7 months
Madan Mettu and Mylandlahalli Ashwini are mutual person
- Eugia Steriles Private LimitedActive 4 years 5 months
Madan Mettu and Santhanam Subramanian are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Eugia Sez?
Eugia Sez has a workforce of 457 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Eugia Sez, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Eugia Sez's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
